Zevra to Participate at Upcoming Investor Conferences
Zevra Therapeutics (NASDAQ: ZVRA), a commercial-stage rare disease therapy company, has announced its participation in two major investor conferences in March 2025. The company's executive leadership team will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, at 10:30 a.m. ET, and the 37th Annual ROTH Conference on March 17, 2025, at 1:00 p.m. PT.
Management will be available for one-on-one meetings with registered attendees at both conferences. Interested parties can access live webcasts of the presentations through the 'Events & Presentations' section on Zevra's Investor Relations website at investors.zevra.com.
Zevra Therapeutics (NASDAQ: ZVRA), un'azienda in fase commerciale che sviluppa terapie per malattie rare, ha annunciato la sua partecipazione a due importanti conferenze per investitori a marzo 2025. Il team dirigenziale dell'azienda presenterà al 45° Annual Health Care Conference di TD Cowen il 5 marzo 2025, alle 10:30 ET, e al 37° Annual ROTH Conference il 17 marzo 2025, alle 13:00 PT.
La direzione sarà disponibile per incontri individuali con i partecipanti registrati a entrambe le conferenze. Le parti interessate possono accedere alle dirette streaming delle presentazioni attraverso la sezione 'Eventi e Presentazioni' sul sito web delle Relazioni con gli Investitori di Zevra all'indirizzo investors.zevra.com.
Zevra Therapeutics (NASDAQ: ZVRA), una empresa en fase comercial dedicada a terapias para enfermedades raras, ha anunciado su participación en dos importantes conferencias de inversores en marzo de 2025. El equipo de liderazgo ejecutivo de la empresa presentará en la 45ª Conferencia Anual de Salud de TD Cowen el 5 de marzo de 2025, a las 10:30 a.m. ET, y en la 37ª Conferencia Anual ROTH el 17 de marzo de 2025, a la 1:00 p.m. PT.
La dirección estará disponible para reuniones uno a uno con los asistentes registrados en ambas conferencias. Las partes interesadas pueden acceder a las transmisiones en vivo de las presentaciones a través de la sección 'Eventos y Presentaciones' en el sitio web de Relaciones con Inversores de Zevra en investors.zevra.com.
Zevra Therapeutics (NASDAQ: ZVRA), 희귀 질병 치료제 상업 단계 회사가 2025년 3월 두 개의 주요 투자자 회의에 참석한다고 발표했습니다. 회사의 경영진 팀은 2025년 3월 5일 오전 10:30 ET에 TD Cowen 제45회 연례 건강 관리 회의와 2025년 3월 17일 오후 1:00 PT에 제37회 연례 ROTH 회의에서 발표할 예정입니다.
경영진은 두 회의에서 등록된 참석자와의 일대일 미팅을 위해 대기할 것입니다. 관심 있는 분들은 Zevra의 투자자 관계 웹사이트의 '이벤트 및 발표' 섹션을 통해 발표의 라이브 웹캐스트에 접근할 수 있습니다. 주소는 investors.zevra.com입니다.
Zevra Therapeutics (NASDAQ: ZVRA), une entreprise en phase commerciale spécialisée dans les thérapies pour les maladies rares, a annoncé sa participation à deux grandes conférences pour investisseurs en mars 2025. L'équipe de direction de l'entreprise présentera lors de la 45e Conférence Annuelle sur la Santé de TD Cowen le 5 mars 2025 à 10h30 ET, et lors de la 37e Conférence Annuelle ROTH le 17 mars 2025 à 13h00 PT.
La direction sera disponible pour des réunions individuelles avec les participants enregistrés lors des deux conférences. Les parties intéressées peuvent accéder aux webinaires en direct des présentations via la section 'Événements & Présentations' sur le site des Relations Investisseurs de Zevra à l'adresse investors.zevra.com.
Zevra Therapeutics (NASDAQ: ZVRA), ein Unternehmen in der kommerziellen Phase für Therapien bei seltenen Krankheiten, hat seine Teilnahme an zwei großen Investorenkonferenzen im März 2025 angekündigt. Das Führungsteam des Unternehmens wird am 5. März 2025 um 10:30 Uhr ET auf der 45. jährlichen Gesundheitskonferenz von TD Cowen und am 17. März 2025 um 13:00 Uhr PT auf der 37. jährlichen ROTH-Konferenz präsentieren.
Das Management wird für persönliche Meetings mit registrierten Teilnehmern auf beiden Konferenzen zur Verfügung stehen. Interessierte Parteien können die Live-Webcasts der Präsentationen über den Bereich 'Veranstaltungen & Präsentationen' auf der Investor Relations-Website von Zevra unter investors.zevra.com abrufen.
- None.
- None.
CELEBRATION, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will participate at the following March events:
- TD Cowen 45th Annual Health Care Conference on Wednesday, Mar. 5, 2025, at 10:30 a.m. ET.
- 37th Annual ROTH Conference on Monday, Mar. 17, 2025, at 1:00 p.m. PT.
Additionally, management will be available for one-on-one meetings with registered attendees at each conference. The live webcasts will be accessible via “Events & Presentations” on the Investor Relations section of Zevra’s website at investors.zevra.com.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage company combining science, data, and patient needs to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.
For more information, please visit www.zevra.com or follow us on X (formerly Twitter) and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra’s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended Dec. 31, 2023, Zevra’s Quarterly Report for the quarter ended Sept. 30, 2024, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Zevra Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
FAQ
When is Zevra Therapeutics (ZVRA) presenting at the TD Cowen Health Care Conference in 2025?
What time is ZVRA's presentation at the 2025 ROTH Conference?
How can investors watch Zevra's (ZVRA) conference presentations in March 2025?
Will ZVRA management be available for one-on-one meetings at the March 2025 conferences?
